Regonix 40mg Tabs. 28`s

Regonix 40mg Tablet contains regorafenib, an oral multi kinase inhibitor that treats metastatic colorectal cancer, gastrointestinal stromal tumours, and hepatocellular carcinoma in adults. Beacon Pharmaceuticals manufactures this targeted therapy for patients who have progressed on earlier cancer treatment. Order Regonix from PakMeds with verified sourcing and reliable nationwide delivery.

Regonix Ingredients and Usage

Regonix 40mg Tablet contains regorafenib, a multi kinase inhibitor that targets several enzymes driving tumour growth and angiogenesis. Beacon Pharmaceuticals manufactures the tablet as a light pink, oval, film coated dose for oral once daily administration. Each tablet delivers 40mg of regorafenib, with a typical treatment dose of 160mg given as four tablets daily.

Doctors prescribe Regonix for adults with metastatic colorectal cancer who have failed fluoropyrimidine, oxaliplatin, irinotecan, anti VEGF, and anti EGFR therapy. The medicine also treats unresectable gastrointestinal stromal tumours after imatinib and sunitinib failure, and hepatocellular carcinoma after sorafenib. Regonix offers a salvage option that prolongs progression free survival in patients with limited remaining treatment choices.

How Does Regonix Work?

Regonix works by blocking multiple receptor tyrosine kinases on tumour cells and the surrounding blood vessels. The drug inhibits VEGFR1, VEGFR2, and VEGFR3, cutting off the new blood vessel formation that solid tumours need to grow. Regonix also targets PDGFR, FGFR, KIT, RET, and the RAF kinases involved in cancer cell survival and proliferation.

This broad spectrum kinase inhibition starves tumours of blood supply, halts cell division signals, and triggers programmed cell death. Clinical trials show Regonix improves median overall survival by around 1.4 months in metastatic colorectal cancer versus placebo. Patients take Regonix once daily for the first 21 days of each 28 day treatment cycle, with a low fat meal.

Regonix Side Effects

Regonix can cause skin, gastrointestinal, and liver side effects, with hand foot skin reaction and hepatotoxicity being the most prominent. Most reactions appear within the first two months of treatment and need close monitoring through regular blood tests.

• Hand foot skin reaction with redness, blistering, and peeling on palms and soles

• Fatigue and weakness

• Diarrhoea and abdominal pain

• New or worsening hypertension

• Decreased appetite and weight loss

• Mucositis and painful mouth sores

• Nausea and vomiting

• Voice changes including hoarseness or dysphonia

• Rash and dry skin

• Elevated liver enzymes (ALT, AST, and bilirubin)

• Bleeding gums, easy bruising, or nosebleeds

• Fever and increased risk of infection

Warnings

• Regonix carries a boxed warning for severe and sometimes fatal liver injury, with most cases occurring within the first two months of treatment.

• Hyperammonemic encephalopathy has occurred in patients with liver dysfunction, liver metastases, or primary liver cancer taking regorafenib.

• Regonix increases the risk of serious bleeding and gastrointestinal perforation, which may require permanent discontinuation.

• Hand foot skin reaction affects more than half of patients and may require dose reduction or temporary treatment interruption.

• Withhold Regonix for at least two weeks before elective surgery and resume only after complete wound healing.

• Strong CYP3A4 inhibitors such as ketoconazole and clarithromycin raise regorafenib levels and increase the risk of toxicity.

• CYP3A4 inducers like rifampin, phenytoin, and St. John's Wort lower drug exposure and reduce treatment efficacy.

• Avoid grapefruit and grapefruit juice during Regonix treatment due to interference with drug metabolism.

• Pregnant women must not use Regonix due to risk of embryo fetal harm, and breastfeeding is not recommended.

• Monitor blood pressure regularly, as Regonix commonly causes new or worsening hypertension during treatment.

Regonix Storage Conditions

Store Regonix 40mg Tablets at controlled room temperature between 20°C and 25°C in the original bottle, which contains a desiccant to absorb moisture. Keep the bottle tightly closed after each use to protect the tablets from humidity, oxygen, and light degradation. Keep Regonix well out of reach of children, and discard any unused tablets through your pharmacy 28 days after first opening the bottle.